Polypharmacy in the Elderly: How to Research and Write the Assignment
A section-by-section guide to researching polypharmacy implications in older adults — covering how to frame the implications analysis, which clinical tools and frameworks apply, how to address avoidance strategies and deprescribing, what the pharmacokinetics section must contain, and how to approach medication compliance with evidence-based sources.
The polypharmacy assignment has three distinct analytical components that most students treat as one: the implications of polypharmacy in the elderly, the strategies for avoiding it, and the clinical approach to safe administration and compliance. Each component requires a different type of evidence and a different analytical framework. Listing side effects of too many medications is not an implications analysis. Saying “reduce medications” is not a strategy. And describing “pill organizers” is not a complete answer on compliance. This guide walks through how to research and construct each component of the assignment with the clinical specificity and source quality that nursing and health sciences courses require.
What This Guide Covers
Understanding the Full Scope of the Assignment
The prompt contains four separate questions presented as one: What are the implications of polypharmacy in the elderly? How can it be avoided? What needs to be done to safely administer medication to older adults? And how can compliance be ensured? Each question deserves substantive treatment. A paper that spends three-quarters of its length on implications and gives one paragraph to each of the remaining three questions has not completed the assignment — it has completed one-quarter of it.
The topic sits at the intersection of pharmacology, geriatrics, and nursing practice. Sources should come from clinical pharmacology journals, nursing practice guidelines, geriatric medicine literature, and evidence-based clinical decision tools — not general health websites or patient-facing materials. Every claim about drug interactions, physiological changes, or clinical screening tools must trace back to a peer-reviewed or professionally published clinical source. The National Institutes of Health (NIH) National Library of Medicine archive is the best free starting point for peer-reviewed pharmacology and geriatrics literature on this topic.
Defining and Contextualizing Polypharmacy
Before analyzing implications, your paper needs a definition section that establishes what polypharmacy means in a clinical context and why older adults are disproportionately affected. The definition is more nuanced than it appears, and getting it right signals clinical literacy from the first paragraph.
Researching the Implications Section
The implications of polypharmacy in the elderly are not simply “more side effects.” The clinical literature organizes them into distinct, mechanistically separate categories — each with its own evidence base and each requiring a different clinical response. Treating all implications as variants of “medication harm” misses the analytical depth the assignment expects. Address each category separately, explain the mechanism, and cite clinical evidence.
Adverse Drug Reactions (ADRs)
The most directly pharmacological implication. ADRs increase non-linearly with the number of medications — the risk approximately doubles when moving from five to eight concurrent drugs. The mechanism involves both predictable pharmacological extensions and unpredictable idiosyncratic responses, compounded by the physiological changes of aging described in the next section.
Drug–Drug Interactions (DDIs)
The number of possible drug pairs grows combinatorially with regimen size. A patient on five medications has 10 possible two-drug combinations; on ten medications, that becomes 45 pairs. Clinically significant DDIs — particularly those involving CYP450 enzyme pathways — are well-documented and your paper should reference specific classes (anticoagulants, NSAIDs, antidepressants) as examples rather than discussing DDIs in abstract terms.
Falls and Fractures
Among the most clinically significant outcomes of polypharmacy in older adults. Psychotropic medications, antihypertensives, diuretics, and opioids each independently increase fall risk through mechanisms including orthostatic hypotension, sedation, and impaired postural reflexes. The cumulative risk from multiple fall-risk medications is documented extensively in the literature and represents a major driver of morbidity and healthcare cost.
Cognitive Impairment
Anticholinergic medications — antihistamines, bladder medications, some antidepressants — have well-established links to cognitive decline, delirium, and increased dementia risk in older adults. The Anticholinergic Cognitive Burden Scale provides a quantifiable framework for assessing this risk. Your paper should explain why older adults are more susceptible to anticholinergic burden even at doses that would not cause cognitive effects in younger patients.
Hospitalizations
Medication-related hospitalizations — admissions caused by ADRs, DDIs, or medication errors — account for a disproportionate share of emergency department visits among older adults. Studies estimate that 30% or more of hospital admissions in this population are medication-related. This implication creates both patient safety and healthcare system cost arguments that strengthen the assignment’s analysis.
Non-Adherence and Cascading Prescribing
Complex regimens reduce adherence, which can cause under-treatment of primary conditions. Paradoxically, polypharmacy also drives “prescribing cascades” — a new medication is prescribed to treat a symptom that is actually an ADR from an existing medication, expanding the regimen rather than addressing the root cause. This self-reinforcing dynamic is a structural implication that extends beyond individual drug harms.
Physiological Changes That Amplify Polypharmacy Risk
A thorough implications section explains why polypharmacy is more dangerous in older adults than in younger patients — not just that it is. The mechanism lies in age-related physiological changes that alter how drugs are absorbed, distributed, metabolized, and eliminated. This pharmacokinetics and pharmacodynamics (PK/PD) content is the scientific foundation of the implications analysis, and omitting it leaves the paper descriptive rather than analytical.
| PK/PD Process | Age-Related Change | Clinical Consequence for Polypharmacy |
|---|---|---|
| Absorption | Reduced gastric acid production, slowed GI motility, decreased splanchnic blood flow | Altered rate and extent of drug absorption; interactions with medications that affect GI pH or motility become more unpredictable |
| Distribution | Decreased lean body mass, increased fat-to-lean ratio, reduced total body water, lower serum albumin | Hydrophilic drugs become more concentrated; lipophilic drugs accumulate; protein-bound drugs compete for reduced albumin binding sites, increasing free drug concentrations |
| Metabolism (Hepatic) | Reduced liver mass and hepatic blood flow; decline in CYP450 enzyme activity | First-pass metabolism reduced; drugs with high hepatic extraction ratios reach systemic circulation at higher concentrations; CYP450 interactions between co-administered drugs produce more pronounced effects |
| Elimination (Renal) | GFR declines approximately 1% per year after age 40; reduced tubular secretion | Renally eliminated drugs and active metabolites accumulate; dose adjustments required for a wide range of medications (digoxin, metformin, NSAIDs, many antibiotics); standard adult doses may be toxic |
| Pharmacodynamics | Altered receptor sensitivity, reduced homeostatic reserves, impaired baroreceptor reflex | Older adults show increased sensitivity to CNS depressants, anticoagulants, and antihypertensives at equivalent plasma concentrations; therapeutic index narrows; adverse effects manifest at doses tolerated by younger patients |
This is a clinically important point worth including in your paper. Because older adults have reduced muscle mass, serum creatinine production decreases — meaning a “normal” serum creatinine level in an 80-year-old may mask significantly impaired GFR. Dosing decisions based on serum creatinine alone without calculating an estimated GFR (using the Cockcroft-Gault or CKD-EPI formula) systematically underestimate renal impairment in this population and are a documented source of polypharmacy-related harm.
Key Adverse Drug Classes to Address
When discussing specific implications, your paper should go beyond generic statements about “many drugs.” Reference the drug classes that the clinical literature most consistently identifies as high-risk in older adults. This specificity demonstrates that the analysis is grounded in pharmacological knowledge, not just general safety awareness.
High-Risk Drug Classes in Older Adults
- Anticoagulants (warfarin, direct oral anticoagulants) — narrow therapeutic index, major bleeding risk, extensive DDI profile; interactions with antibiotics, NSAIDs, and antiplatelet agents are common
- Anticholinergics — cognitive impairment, urinary retention, constipation, falls; cumulative anticholinergic burden from multiple drugs with anticholinergic properties
- Benzodiazepines and Z-drugs — falls, hip fracture, delirium, respiratory depression; listed in Beers Criteria as drugs to avoid or use with caution in older adults
- NSAIDs — GI bleeding, renal impairment, fluid retention, hypertension; interactions with antihypertensives and anticoagulants
- Antihypertensives — orthostatic hypotension and falls when multiple agents are combined or doses are not adjusted for age-related baroreceptor changes
- Insulin and sulfonylureas — hypoglycemia risk increases with renal impairment and erratic food intake common in older adults
The Prescribing Cascade — A Specific Pattern to Explain
A prescribing cascade occurs when an ADR from Drug A is misidentified as a new disease symptom and treated with Drug B, which itself causes an ADR treated with Drug C. Classic examples are well-documented:
- NSAID → hypertension → antihypertensive prescribed
- Calcium channel blocker → ankle edema → diuretic prescribed
- Metoclopramide → drug-induced Parkinsonism → levodopa prescribed
- ACE inhibitor → dry cough → cough suppressant prescribed
Your paper should describe this pattern explicitly — it is one of the most clinically important mechanisms by which polypharmacy self-perpetuates, and citing a specific cascade example makes the implication concrete and credible.
How Polypharmacy Can Be Avoided
The avoidance section requires more than “review medications regularly.” It needs to address the specific clinical processes, decision tools, and care coordination strategies that the evidence base supports. Three areas deserve detailed treatment: medication reconciliation, explicit criteria-based screening tools, and structured prescribing review processes.
-
Medication Reconciliation at Every Care Transition
Medication reconciliation — the process of creating a complete, accurate medication list and comparing it against orders at each care transition (admission, discharge, transfer) — is the primary systemic intervention for catching polypharmacy problems before they cause harm. The Joint Commission mandates medication reconciliation as a National Patient Safety Goal. Your paper should describe what reconciliation involves (obtaining a complete list including OTC drugs, herbals, and supplements; comparing it to current orders; resolving discrepancies) and explain where it most commonly fails (at hospital discharge, when patients transition from inpatient to primary care without a reconciled list).
-
Explicit Prescribing Criteria as Screening Tools
Several validated clinical tools exist specifically to identify inappropriate prescribing in older adults. The Beers Criteria (American Geriatrics Society) and the STOPP/START criteria (Screening Tool of Older Persons’ Prescriptions / Screening Tool to Alert doctors to Right Treatment) are the two most widely used. Both provide explicit, evidence-based lists of medications to avoid and medications that are commonly omitted when clinically needed. Your paper should describe how each tool is used in a medication review and what evidence supports their efficacy in reducing ADRs and inappropriate prescribing.
-
Interdisciplinary Medication Review
A single prescriber reviewing a complex regimen without the involvement of a clinical pharmacist is structurally less effective than an interdisciplinary review that includes pharmacist expertise. Clinical pharmacist-led medication reviews are associated with reductions in inappropriate prescribing, ADRs, and medication costs in older adult populations. Your paper should describe the pharmacist’s specific role (identifying DDIs, recommending dose adjustments based on renal function, flagging Beers Criteria medications) and cite evidence for the effectiveness of this intervention.
-
Patient and Prescriber Education
A structural driver of polypharmacy is that patients see multiple specialist prescribers who each operate within their domain without visibility into the full regimen. Interventions that improve communication — shared electronic health records, designated medication manager roles, patient-carried medication cards — address this coordination failure. Similarly, educating patients about the risk of adding OTC medications, supplements, and herbal products to an existing prescription regimen without pharmacist review addresses the “hidden polypharmacy” component.
-
Addressing Overprescribing Culture and Guideline Limitations
Many clinical practice guidelines are developed for single-disease management in patients without comorbidities — the exact opposite of the typical older adult patient. Following multiple single-disease guidelines simultaneously often produces a polypharmacy regimen that no guideline intended. Your paper should acknowledge this systemic issue: the problem is not just individual prescribing decisions but guidelines that do not account for multimorbidity. Some researchers argue for updated guidelines that incorporate polypharmacy risk alongside disease-specific recommendations.
Clinical Tools: Beers Criteria and STOPP/START
Both the Beers Criteria and STOPP/START criteria deserve dedicated paragraphs rather than a passing mention, because they represent the evidence-based operational standard for polypharmacy reduction in clinical practice — and your paper is expected to demonstrate familiarity with these tools.
American Geriatrics Society Beers Criteria
Published and regularly updated by the American Geriatrics Society (most recent update 2023), the Beers Criteria is an expert-consensus, evidence-based list of potentially inappropriate medications (PIMs) in adults aged 65 and older. It is organized into five categories: medications to avoid regardless of diagnosis, medications to avoid in specific conditions, medications to use with caution, drug–drug interactions to avoid, and medications requiring dose adjustments for renal function.
For your paper, key points to make about the Beers Criteria are: it is not a prohibition list (a medication on the list may still be appropriate in specific circumstances with monitoring), it is updated every three years to reflect new evidence, and it is a starting point for clinical judgment rather than a substitute for it. Cite the AGS directly as a source — it is available free at the American Geriatrics Society website.
STOPP/START Criteria
Developed in Ireland and widely used in European clinical practice, the STOPP/START criteria operate on two complementary dimensions: STOPP (Screening Tool of Older Persons’ Prescriptions) identifies medications that should be stopped; START (Screening Tool to Alert doctors to Right Treatment) identifies medications that are clinically indicated but under-prescribed. This dual approach addresses both over-prescribing and under-prescribing — an important distinction for your paper, since polypharmacy management is not only about reducing drug counts but about optimizing the regimen.
Comparative studies suggest STOPP/START identifies a higher proportion of inappropriate prescribing than Beers Criteria alone, and the two tools have complementary strengths. Using both in a medication review is more comprehensive than using either one alone.
Deprescribing as a Framework
Deprescribing — the planned, supervised process of dose reduction or discontinuation of medications that are no longer indicated or that are causing harm — is the clinical framework most directly relevant to the avoidance section of this assignment. It is distinct from simply stopping medications and deserves a dedicated paragraph.
The Five Steps of a Structured Deprescribing Process
Your paper can organize the deprescribing discussion around the clinical steps that systematic deprescribing frameworks recommend. These steps reflect the evidence base for reducing polypharmacy safely:
- Compile the complete medication list: Include all prescription drugs, OTC medications, supplements, and herbal products — many patients do not disclose non-prescription products unless directly asked.
- Calculate the individual’s overall medication burden: Apply tools such as the Anticholinergic Cognitive Burden Scale, the Drug Burden Index, or Beers Criteria to assess cumulative risk, not just individual drug appropriateness.
- Assess each medication for continued indication: Is the original indication still present? Is the medication achieving its therapeutic goal? Has the patient’s condition, goals of care, or life expectancy changed in ways that alter the benefit-harm calculus?
- Prioritize medications for discontinuation: Focus first on those with the highest risk relative to benefit — medications on the Beers Criteria, those with duplicative mechanisms, those treating ADRs of other drugs (prescribing cascades), and those whose indication has resolved.
- Monitor and support withdrawal: Some medications require gradual tapering (antidepressants, corticosteroids, opioids, benzodiazepines) to avoid rebound effects. Patient education and scheduled follow-up are required components of safe deprescribing, not optional add-ons.
Safe Medication Administration in Older Adults
The third component of the prompt — what needs to be done to safely administer medication to older adults — requires going beyond basic medication administration principles to address the age-specific considerations that create additional risk in this population. The “rights of medication administration” framework (right patient, right drug, right dose, right route, right time) applies, but each right has specific clinical implications when applied to an older adult with polypharmacy.
Dose Adjustments for Physiological Changes
Because of the pharmacokinetic changes described earlier — reduced renal clearance, altered hepatic metabolism, lower albumin binding capacity, increased fat-to-lean ratio — standard adult doses are frequently inappropriate for older patients. Your paper should address how to approach dosing adjustments: calculating estimated GFR rather than relying on serum creatinine, using weight-based dosing where appropriate, starting with the lowest effective dose (“start low, go slow” is the clinical principle), and titrating upward based on response and tolerability rather than applying population-average target doses.
Administration Timing and Food–Drug Interactions
Several medication classes require specific timing relative to meals, other medications, or daily activity schedules to maximize effectiveness and minimize harm in older adults. Bisphosphonates require fasting and upright posture for 30–60 minutes after administration. Levothyroxine absorption is impaired by calcium, iron supplements, and many antacids. Warfarin response is affected by vitamin K intake from diet. For an older adult on a complex regimen, the interaction between food, timing, and multiple medications creates an administration complexity that affects both safety and effectiveness — and that nurses must be equipped to identify, teach, and monitor.
Route-Specific Considerations
Dysphagia — difficulty swallowing — affects a significant proportion of older adults, particularly those in long-term care settings. Crushing tablets or opening capsules to facilitate swallowing is common practice but carries clinical risks: some medications (extended-release formulations, enteric-coated tablets) must not be crushed because crushing destroys the formulation that controls drug release rate or protects the stomach lining. Your paper should address the clinical obligation to verify whether a medication can safely be altered before administering it in a modified form, and name the resource for this verification (the Institute for Safe Medication Practices publishes a Do Not Crush list used in clinical practice).
High-Alert Medications — Extra Precautions
The Institute for Safe Medication Practices (ISMP) High-Alert Medications list identifies drugs that carry a heightened risk of causing significant patient harm when used in error. For older adults on polypharmacy regimens, the most clinically relevant high-alert medications include anticoagulants (particularly warfarin and injectable heparins), concentrated electrolytes, insulin, opioids, and neuromuscular blocking agents. Your paper should describe what “high-alert” means operationally — the additional verification steps, independent double-checks, and patient monitoring protocols that clinical settings apply to these medications specifically because of their narrow safety margins.
Ensuring Medication Compliance in Older Adults
Compliance — or more accurately, adherence — is the fourth analytical component of this assignment. The terminology distinction matters for a clinical paper: “compliance” implies passive patient obedience to prescriber instructions; “adherence” implies an active patient role in a shared decision-making process. Most current clinical and nursing literature uses adherence, and your paper should reflect that language shift and explain why it matters.
Non-adherence in older adults with polypharmacy is not primarily a motivational problem — it is a systems and complexity problem. Regimens involving multiple medications with different dosing frequencies, different food interactions, different storage requirements, and different monitoring obligations create a cognitive and logistical burden that increases with age-related changes in memory and executive function. Effective compliance interventions address that complexity directly.
Regimen Simplification
The single most evidence-supported intervention for improving adherence in polypharmacy patients is reducing regimen complexity. Strategies include: consolidating medications to once-daily dosing where therapeutically equivalent alternatives exist, using fixed-dose combination products where available and appropriate, eliminating duplicative medications (two drugs from the same class), and timing all medications to the same daily anchor (e.g., all morning medications with breakfast). Simplification does not mean reducing the number of medications arbitrarily — it means reducing the cognitive and logistical burden of taking them correctly.
Patient and Caregiver Education
Education interventions must be tailored to the patient’s health literacy, cognitive status, sensory abilities (vision, hearing), and preferred learning modality. Written instructions at an appropriate reading level, large-print medication schedules, pictographic instructions for patients with limited literacy, and verbal teach-back techniques are all evidence-supported components of medication education in older adults. Critically, education must also address what to do if a dose is missed — a specific concern with anticoagulants, antiepileptics, and antihypertensives — because incorrect self-management of missed doses is a common source of harm.
Adherence Aids and Practical Tools
Medication organization tools — pill organizers (weekly or multi-dose), blister packaging, and automated medication dispensers — reduce the cognitive burden of tracking a complex regimen and provide a visible cue when a dose has been taken or missed. Electronic medication reminders (smartphone apps, automatic pill dispensers with alarms) address the specific adherence challenge of forgetting, which is among the most common self-reported reasons for missed doses in older adults. Your paper should describe specific tools and cite evidence for their effectiveness rather than listing them as generic options.
Shared Decision-Making and Patient Goals
Long-term adherence with medications that do not produce perceptible effects (antihypertensives, statins, bisphosphonates) is consistently lower than adherence with medications whose effect the patient can feel. Engaging older adults in explicit conversations about their medication goals, their concerns about side effects, and their values around quality of life versus disease prevention is both ethically appropriate and pragmatically effective — patients who understand why a medication is prescribed and who have had their concerns addressed are more likely to take it consistently. The clinical literature on shared decision-making in geriatric pharmacotherapy supports this approach as a compliance intervention, not just an ethical obligation.
Regular Medication Reviews and Follow-Up
Scheduled medication reviews — distinct from acute care visits — provide structured opportunities to assess adherence, identify side effects that may be causing patients to self-discontinue medications, update the regimen based on changes in health status, and reinforce education. In primary care settings, annual comprehensive medication reviews for patients on five or more medications are recommended by geriatric care guidelines. Monitoring adherence through pill counts, prescription refill records, or direct patient questioning should be a routine component of these reviews, not an afterthought.
Sources That Meet Academic Standards for This Topic
This assignment requires clinical and research sources — not health education websites or general nursing textbook chapters used as primary sources. The following source types are appropriate, and the databases listed will give you access to the peer-reviewed content the topic demands.
| Source Type | What It Supports | Where to Access |
|---|---|---|
| American Geriatrics Society Beers Criteria | Inappropriate prescribing screening; avoidance strategies; specific drug class risks | American Geriatrics Society website (americangeriatrics.org); also published in JAGS (Journal of the American Geriatrics Society) |
| STOPP/START Criteria publications | Inappropriate prescribing detection; comparison with Beers; over-prescribing and under-prescribing | PubMed/MEDLINE; original publication in Age and Ageing journal; open-access versions on NIH PubMed Central |
| Peer-reviewed pharmacology and geriatrics journals | PK/PD changes with aging; ADR prevalence; DDI evidence; deprescribing outcomes | PubMed/MEDLINE (free abstracts, many full texts); CINAHL (library access); Drugs & Aging; Journal of Gerontology; Annals of Long-Term Care |
| Institute for Safe Medication Practices (ISMP) | High-alert medications; do-not-crush list; medication error prevention; safe administration practices | ismp.org — many publications freely available; ISMP Medication Safety Alert newsletter |
| CDC / NIH statistical and epidemiological data | Prevalence statistics; hospitalization rates; fall injury data; medication use in older adults | cdc.gov; nih.gov; NIH NLM PubMed Central (pubmed.ncbi.nlm.nih.gov) |
| Clinical practice guidelines | Safe administration standards; adherence interventions; medication review protocols | National Guideline Clearinghouse (AHRQ); professional organizations (ANA, AGS, ASHP); specialty society websites |
Source 1 — American Geriatrics Society 2023 Beers Criteria. Published in the Journal of the American Geriatrics Society. The most current version is the 2023 update. Freely accessible in summary form at americangeriatrics.org; full text available through JAGS or institutional library access. Cite as: American Geriatrics Society Beers Criteria® Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052–2081.
Source 2 — Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. E. (2017). What is polypharmacy? A systematic review of definitions. BMC Geriatrics, 17(230). Open access at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737124/ — Provides the definitional framework, reviews different threshold definitions across the literature, and contextualizes why the definition matters for both research and clinical practice.
Source 3 — ISMP List of High-Alert Medications. Available at ismp.org. Use for the safe administration section — specifically for the discussion of medications requiring additional verification procedures and enhanced monitoring in clinical settings, including those most commonly involved in polypharmacy-related errors in older adults.
How to Structure the Paper
The assignment prompt has four parts, which map directly to four sections of the paper body. Before writing, draft a brief outline that allocates approximately equal page space to each section — otherwise the implications section will expand to fill the paper while avoidance, safe administration, and compliance each get one underdeveloped paragraph.
Introduction (half page): Define polypharmacy (quantitative and qualitative definitions), contextualize prevalence in the older adult population, state the significance of the problem (ADR rates, hospitalization rates, healthcare costs), and preview the four analytical areas the paper will address.
Section 1 — Implications (one page): Age-related PK/PD changes that amplify risk → ADRs and DDIs → falls and cognitive impairment → hospitalizations → prescribing cascades. Each implication explained mechanistically with a cited source. Do not simply list — explain why aging makes each implication more severe than in younger patients.
Section 2 — Avoidance Strategies (half to three-quarters page): Medication reconciliation → Beers Criteria and STOPP/START → interdisciplinary pharmacist review → deprescribing framework → addressing multimorbidity and guideline limitations. Each strategy connected to specific clinical evidence.
Section 3 — Safe Administration (half page): Dose adjustment principles (start low, go slow; GFR-based renal dosing) → timing and food interactions → route modifications and the do-not-crush issue → high-alert medications and verification protocols.
Section 4 — Ensuring Compliance (half page): Regimen simplification → patient education with teach-back → adherence tools → shared decision-making → scheduled medication reviews. Use “adherence” not “compliance” language; connect to the complexity burden.
Conclusion (quarter page): Synthesize how the four areas interconnect — polypharmacy implications drive the need for avoidance strategies; age-specific physiology requires adjusted administration; and complexity of the regimen creates the compliance challenge that medication reviews address. No new information.
At 300 words per half-page (standard double-spaced 12pt), this structure produces approximately 1,050–1,200 words of body text — roughly 4 double-spaced pages plus title page and references. Adjust based on your specific page length requirement.
Where Most Papers Fall Short
Implications Listed, Not Explained Mechanistically
“Polypharmacy can cause falls, confusion, and hospitalizations.” This lists outcomes without explaining why aging physiology makes these outcomes more likely, or how the pharmacokinetic and pharmacodynamic changes of aging mediate each harm. Without mechanism, the analysis is descriptive, not clinical.
Instead
For each implication, write two sentences: one naming and defining the outcome, one explaining the physiological or pharmacological mechanism by which polypharmacy in an aging body produces it. Example: falls result from polypharmacy-induced orthostatic hypotension and sedation, which are amplified by impaired baroreceptor reflexes and reduced hepatic clearance of psychotropic drugs in older adults.
Avoidance Section That Only Mentions Medication Reviews
Recommending “regular medication reviews” without specifying who conducts them, which validated screening tools are used, what the review examines, or what evidence supports the intervention. A medication review is the container for the tools and clinical reasoning — the paper needs to describe what goes inside it.
Instead
Name the specific tools (Beers Criteria, STOPP/START), describe the pharmacist’s role in interdisciplinary review, explain the deprescribing process with its specific steps, and cite evidence that each intervention reduces inappropriate prescribing or adverse outcomes. Generic recommendations with no clinical specificity do not demonstrate understanding of clinical practice.
Safe Administration Limited to “The Five Rights”
Reciting the rights of medication administration without addressing the age-specific considerations that make each right more complex in older adults. The five rights are entry-level knowledge; a graduate or advanced nursing paper needs to go further — renal dosing, the do-not-crush issue, high-alert medications, and the clinical implications of altered PK.
Instead
Frame the five rights as starting points and then address what each requires in the specific context of an older adult on polypharmacy: right dose requires GFR-based adjustment; right route requires dysphagia assessment and crush-safety verification; right drug requires cross-checking against Beers Criteria. The specificity is what demonstrates clinical competency.
Compliance Section Focused Only on Tools and Reminders
Listing pill organizers, smartphone reminders, and medication calendars as the primary compliance strategy, without addressing the structural complexity problem that drives non-adherence or the shared decision-making component that affects long-term behavior. Tool recommendations without evidence citations are suggestions, not clinical analysis.
Instead
Lead with regimen simplification (the most evidence-supported intervention), then address education quality (health literacy, teach-back), then practical tools with evidence for their effectiveness, then shared decision-making as a sustained adherence strategy. Cite evidence for each intervention rather than presenting recommendations without support.
Sources from Health Websites or Patient-Facing Materials
Citing Mayo Clinic, WebMD, or patient handout PDFs as primary sources in a nursing or pharmacology paper. These are written for patients, not clinicians, and do not contain the clinical specificity or evidence base that academic nursing papers require. Instructors recognize these source types and grade accordingly.
Instead
Use PubMed for peer-reviewed articles, CINAHL for nursing literature, the American Geriatrics Society for the Beers Criteria, ISMP for medication safety standards, and CDC/NIH for epidemiological data. Every factual claim about drug risks, physiological changes, or clinical tools needs to trace back to a citable clinical source.
Frequently Asked Questions
Putting the Assignment Together: How the Four Sections Connect
The four analytical components of this assignment are not independent sections — they form a clinical logic chain. The physiological changes of aging explain why the implications of polypharmacy are more severe in older adults than in younger patients. Understanding those implications tells you which specific risks the avoidance strategies need to target — reducing falls means removing or reducing fall-risk medications; reducing cognitive impairment means calculating and addressing anticholinergic burden; reducing hospitalizations means identifying and eliminating prescribing cascades. Safe administration practices are grounded in the same physiological knowledge — dose adjustments, route selection, and high-alert monitoring protocols all derive from the PK/PD changes described in the implications section. And compliance interventions are most effective when they address the specific barriers that polypharmacy creates — complexity, side effects that prompt self-discontinuation, and inadequate shared decision-making.
Before submitting, read the paper in sequence and ask: does each section connect back to the previous one? Does the avoidance section target the specific implications I described? Does the compliance section address the complexity of the regimen I described in the implications? Are all clinical tools and drug class examples supported by a cited source? These connections are what transform a set of four topically related paragraphs into a coherent clinical analysis.
For direct support with this assignment — locating and integrating peer-reviewed clinical sources, developing the pharmacokinetics discussion, building the deprescribing or compliance sections, or reviewing a completed draft for clinical accuracy and APA formatting — our nursing and health sciences writing team works specifically with pharmacology, gerontology, and clinical practice coursework.
Continue with: advanced nursing degree help · nursing care plan writing · literature review writing · research paper writing · proofread my research paper.